ArticleUltrasonography (Seoul, Korea)2026
Malignancy rate of cervical lymph nodes based on concordance of ultrasound and computed tomography imaging features in patients with thyroid cancer.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study analyzed the malignancy rate of lymph nodes (LNs) according to the concordance of ultrasound (US) and computed tomography (CT) imaging features in patients with thyroid cancer.
methodsA retrospective analysis was performed of 277 cytopathologically confirmed cervical LNs (53.1% malignant) from 228 patients with thyroid cancer who underwent US-guided biopsy and preoperative US and CT. Malignancy rates were calculated according to the concordance of US and CT imaging features by matching cortical hyperechogenicity or abnormal vascularity on US (US-echo-vascularity) with strong or heterogeneous enhancement on CT (CT-enhancement), cystic changes on US (US-cystic) with cystic changes on CT (CT-cystic), and echogenic foci on US (US-EF) with calcifications on CT (CT-calcification).
resultsMalignancy rates were significantly higher in positively concordant cases across all imaging features compared to negatively concordant cases (US-echo-vascularity/CT-enhancement: 93.5% vs. 8.2%, P<0.001; US-cystic/CT-cystic: 94.4% vs. 41.3%, P<0.001; and US-EF/CT-calcification: 84.4% vs. 34.5%, P<0.001). Discordance in US-cystic/CT-cystic (96.3% vs. 94.4%, P=0.735) or US-EF/CT-calcification (86.0% vs. 84.4%, P=0.873) findings showed malignancy rates comparable to those for positively concordant cases. However, discordance in US-echo-vascularity/CT-enhancement resulted in a significantly lower malignancy rate than in positively concordant cases (66.8% vs. 93.5%, P<0.001). In this discordant group, CT demonstrated a higher diagnostic odds ratio (3.896 vs. 0.257, P=0.002) and higher sensitivity (81.1% vs. 18.9%, P<0.001) than US.
conclusionPositive US/CT concordance across all imaging features, as well as discordance in US-cystic/CT-cystic or US-EF/CT-calcification, strongly suggested LN metastasis. CT-enhancement was particularly reliable when discordant with US-echo-vascularity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.